Thalidomide

Generic Name: Thalidomide

Brand Names: Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₀N_₂O_₄

CAS Number: 50-35-1

Unique Ingredient Identifier: 4Z8R6ORS6L

Background: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.

Indication: Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions: Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma

Associated Therapies: -

Clinical Trials

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

Phase 2

Terminated

Conditions: Chronic Prostatitis
Pelvic Pain

Interventions: Drug: Thalidomide

First Posted Date: 2006-03-10

Last Posted Date: 2013-08-05

Lead Sponsor: Kenneth Peters, MD

Target Recruit Count: 9

Registration Number: NCT00301405

Locations: 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib
Drug: thalidomide

First Posted Date: 2006-02-07

Last Posted Date: 2018-03-01

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 30

Registration Number: NCT00287872

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Use of Thalidomide in Patients With Arachnoiditis

Phase 2

Completed

Conditions: Arachnoiditis

First Posted Date: 2006-01-31

Last Posted Date: 2008-12-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 3

Registration Number: NCT00284505

Locations: 🇺🇸
Washington University Pain Management Center, St. Louis, Missouri, United States

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine hydrochloride
Drug: thalidomide
Procedure: conventional surgery

First Posted Date: 2006-01-25

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 22

Registration Number: NCT00281827

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States
🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer

Phase 2

Conditions: Liver Cancer

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 47

Registration Number: NCT00276705

Locations: 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Royal London Hospital, London, England, United Kingdom
🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom

and more 17 locations

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Phase 2

Completed

Conditions: Myelodysplastic/Myeloproliferative Diseases
Myelodysplastic Syndromes
Chronic Myeloproliferative Disorders
Leukemia

First Posted Date: 2006-01-11

Last Posted Date: 2020-07-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT00274820

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: thalidomide
Drug: zoledronic acid

First Posted Date: 2005-12-08

Last Posted Date: 2011-07-21

Lead Sponsor: Gleneagles Hospital

Target Recruit Count: 56

Registration Number: NCT00263484

Locations: 🇮🇳
Christian Medical College, Vellore, Tamil Nadu, India
🇮🇳
Tata Memorial Hospital, Mumbai, India
🇰🇷
Chonnam National University Hwasun Hospital, Kwangju, Korea, Republic of

and more 7 locations